The findings, which were presented at the 61st ERA Congress Friday, suggest that receiving a weekly injection of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, may help prevent complications like chronic kidney disease and end-stage renal disease that often occur alongside obesity
Constipation On the opposite end, constipation affected 24.2% of semaglutide 2.4 mg users versus 11.1% on placebo in the STEP trials
Telehealth platforms offering compounded tirzepatide use their own prescriber networks
Always check your vial label before drawing
With medical guidance and ongoing support, patients can achieve not only significant weight loss but also improved hormonal balance, better energy, and long-term health benefits
It also slows digestion further, increasing water retention throughout the digestive tract